Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | YES1 | P07947 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.35 |
| ▸ | TAB1 | Q15750 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | MTAP | Q13126 | 4/20 | 0.34 |
| ▸ | JAK3 | P52333 | 4/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27975802 | 0.81 | MAP3K7 (0.41) | RETTRPA1MAP3K7TAB1MTAP | |
| SCHEMBL25776394 | 0.76 | TRPA1 (0.51) | RETTRPA1MAP3K7TAB1IRAK4 | |
| SCHEMBL28057851 | 0.76 | JAK3 (0.46) | TRPA1JAK3 | |
| SCHEMBL20125404 | 0.70 | JAK3 (0.43) | RETTRPA1MAP3K7TAB1JAK3 | |
| SCHEMBL28826847 | 0.70 | TRPA1 (0.35) | RETTRPA1MAP3K7TAB1IRAK4 | |
| SCHEMBL19743349 | 0.70 | CHEK1 (0.41) | RETTRPA1MAP3K7TAB1IRAK4 | |
| SCHEMBL23629999 | 0.69 | MAP3K7 (0.40) | MTORABL1FYNYES1RET | |
| SCHEMBL28057853 | 0.66 | TRPA1 (0.36) | RETTRPA1MAP3K7TAB1IRAK4 | |
| SCHEMBL31570704 | 0.65 | MAP3K7 (0.37) | RETTRPA1MAP3K7TAB1IRAK4 | |
| SCHEMBL10259826 | 0.64 | AKT1 (0.45) | RETTRPA1IRAK4PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-112714649-B | Cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| EP-3848054-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | Daiichi Sankyo Company, Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-112714649-A | Novel cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2021-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | MTOR 3895/4885ABL1 831/4885FYN 1049/4885 |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | MTOR 4051/4885ABL1 1102/4885FYN 1203/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | MTOR 4051/4885ABL1 1102/4885FYN 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.